

# Hope Is Here in CLL

## *Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients*

### Activity Description

Oncology nursing care is critical for the effective delivery of therapy in chronic lymphocytic leukemia (CLL), where the emergence of multiple novel agent classes, such as BTK and BCL-2 inhibitors, has transformed disease management. Furthermore, oncology nurses will play a key role in integrating the next wave of novel therapeutics, which range from newer BTK-based strategies to CAR-T cell therapy options. As always, nurses are perfectly placed to enhance modern CLL care by counseling patients on the benefits and risks of novel therapeutics across the spectrum of disease.

This “Clinical Consults” activity, developed in collaboration with the CLL Society, features nurse-to-nurse, case-based education designed to illustrate how nurses can decisively implement the latest recommendations for effective use of innovative therapeutics in CLL. The case-centric “Clinical Consult” segments will provide guidance on best practices for using first- and second-generation BTK inhibitor- and BCL-2 inhibitor-based regimens while preparing for the emergence of cellular therapy. Nurses remain the common thread linking informed CLL treatment decisions to improvement in patients—find out how during this educational session!

### Educational Objectives

Upon completion of this activity, participants should be better able to:

- Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy
- Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes
- Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment

### Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other healthcare providers involved in the care of patients with CLL.


### Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

### Accreditation, Support, and Credit

 In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Support

This activity is supported through independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

### Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

### ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows: 1.0 point: Cellular Collection, Preparative Regimens, and Infusion, Foundations of Transplant, Oncology Nursing Practice, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PeerView  
Live



This NCPD/ILNA activity is provided by PVI, PeerView Institute for Medical Education.

This activity has been developed in partnership with the CLL Society.

This activity is supported through independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

# Hope Is Here in CLL

## *Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients*

### Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to *The Standards for Integrity and Independence in Accredited Continuing Education*. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. **All relevant conflicts of interest have been mitigated prior to the commencement of the activity.**

### Faculty/Planner Disclosures

Chair/Planner

Amy Goodrich, CRNP

Nurse Practitioner

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland

Amy Goodrich, CRNP, has a financial interest/relationship or affiliation in the form of:

*Consultant and/or Advisor* for AbbVie Inc; AstraZeneca; BeiGene; Fresenius Kabi; Genentech, Inc.; and Sanofi.

Faculty/Planner

Kristen Battiato, MSN, RN, AGNP-C

Memorial Sloan Kettering Cancer Center

New York, New York

Kristen Battiato, MSN, RN, AGNP-C, has a financial interest/relationship or affiliation in the form of:

*Consultant and/or Advisor* for AbbVie.

Faculty/Planner

Christina Russomanno, RN, MS, NP-C

Nurse Practitioner, Leukemia Service

Director of Nursing, Outpatient Hematology/Oncology

Columbia University Irving Medical Center

Herbert Irving Comprehensive Cancer Center

New York, New York

Christina Russomanno, RN, MS, NP-C, has no financial interests/relationships or affiliations in relation to this activity.

### Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

### Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### About This NCPD/ILNA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

PeerView  
Live



CLL SOCIETY

This NCPD/ILNA activity is provided by PVI, PeerView Institute for Medical Education.

This activity has been developed in partnership with the CLL Society.

This activity is supported through independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.